Pediatric Multiple Sclerosis Clinical Trial
Official title:
Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes
Up to 65% of patients with multiple sclerosis (MS) experience cognitive dysfunction. Diminution of mental capacity has a pervasive and profound impact on their quality of life. Subtle changes in white matter predict cognitive changes in these patients but how this disrupts brain function remains unclear. Development of effective therapeutics to restore normal cognition hinges on elucidating these functional changes. The investigators seek to uncover the patho-physiological basis for cognitive decline in MS. The investigators hypothesize that cognitive decline originates from disrupted gamma oscillations and that gamma oscillations are disrupted by molecular changes triggered by demyelination.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01396343 -
Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis
|
||
Completed |
NCT04660227 -
Exercise Training in Pediatric-Onset Multiple Sclerosis Patients
|
N/A | |
Completed |
NCT03137602 -
ATOMIC (Active Teens With MultIple sClerosis) Teens: A Feasibility Study
|
N/A | |
Completed |
NCT03067025 -
Sleep, Physical Activity and Multiple Sclerosis Symptoms in Pediatric Multiple Sclerosis
|
||
Completed |
NCT04441229 -
Mobile Attentional Bias Modification Training in Pediatric MS
|
N/A | |
Recruiting |
NCT04782466 -
ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program
|
N/A |